Attenuation of haemodynamic response to tracheal intubation with oral gabapentin and midazolam in breast cancer patients

Attenuation of haemodynamic response to tracheal intubation with oral gabapentin and midazolam in breast cancer patients: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15943548

Enrollment

Registered

2017-03-20

Start date

2017-02-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Modified radical mastectomy under general anaesthesia Surgery

Interventions

Patients are randomised into two groups: 1. Oral gabapentin 800 mg plus 7.5 mg midazolam 2. Oral gabapentin 800 mg Both drugs are given 90 min prior to surgery and patients are followed up to 24 hour

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. ASA1 or 2 patients 2. Between 18 to 65 years of age 3. Undergoing modified radical mastectomy under general anaesthesia

Exclusion criteria

Exclusion criteria: 1. Allergy to gabapentin or midazolam 2. Severe renal or liver insufficiency 3. Patient refusal

Design outcomes

Primary

Measure	Time frame
1. Heart rate measured by electrocardiogram and pulse oximetry 2. Blood pressure measured by non invasive blood pressure monitor Measured at baseline and at 0, 1, 3, 5, 10, 15 and 30 minutes of intubation	—

Secondary

Measure	Time frame
1. Sedation measured using Ramsay Sedation Scale 2. Side effects (e.g. nausea or vomiting) recorded by physician staff Recorded over 24 h postoperatively	—

Countries

Egypt

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026